MedWatch

Eli Lilly and Boehringer drug gets head start at FDA

Jardiance has been awarded "priority review" status by the US Food and Drug Administration in a new indication.

Photo: MIKE SEGAR/REUTERS / X90033

Eli Lilly and its partner Boehringer Ingelheim have been granted special status at the FDA for their drug Jardiance, to speed up its journey to market as a preventive therapy for heart failure in patients who are not suffering from reduced ventricle functioning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs